Why Are Silverback Therapeutics Shares Falling On Monday?
- Silverback Therapeutics Inc (NASDAQ: SBTX) stock dropped to the lowest level since its IPO in December 2020 in reaction to interim data from SBT6050 Phase 1/1b trial for solid tumors.
- The trial in advanced or metastatic HER2-expressing or amplified solid cancer was designed to evaluate SBT6050 as a monotherapy and combined with Merck & Co Inc's (NYSE: MRK) Keytruda (pembrolizumab).
- Data will be presented at the upcoming European Society for Medical Oncology (ESMO) 2021 Congress.
- 14 patients were evaluable for the response after treatment of four dose levels of SBT6050 ranging from 0.15 mg/kg to 1.2 mg/kg
- The best overall response was PR (n=1), SD (n=3), and PD (n=10).
- SBT6050 given alone or in combination with pembrolizumab has a manageable safety profile.
- The data in the abstract had a cut-off data date of April 4, 2021.
- However, the Company said that the upcoming poster would include additional data with a cut-off date of August 1.
- Price Action: SBTX stock is down 22.8% at $15.01 during the market session on the last check Monday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Biotech News Short Ideas Health Care Small Cap Movers Trading Ideas General
